Connect with us

News

Dental Implants Market 2019 Detailed Analysis of Current Industry Figures with Forecasts Growth By 2025

Dental Implants Market Size By Product (Tapered Implants, Parallel Walled Implants), By Material (Titanium, Zirconium), By End-use (Hospitals, Dental Clinics)

gbafNews28

With the right mix of technological advancements and advanced dental practices, the dynamism of dental implants market has significantly improved in the recent years. Not to mention, the escalating geriatric population that is usually prone to oral health problems and the rising adoption of cosmetic dentistry have set the stage lucrative for dental implants market growth. Reliable data validates that over 35 million Americans are missing at least one tooth in one or both the jaws and more than 15 million people in U.S. have crown & bridge replacements for missing teeth. Estimates further claim that more than 3 million people in U.S. have implants and the number is growing by 500,000 every year.

The aforementioned data bears a significant testimony to the fact that the global dental implants industry is poised to be one of the fastest growing sectors of the overall healthcare ecosystem. Dental practice, however is now getting a renewed traction with the advancement in latest software and hardware solutions that are successfully providing useful solutions to handle dental techniques and management.

Request sample copy of this report @ https://www.gminsights.com/request-sample/detail/2684

Robot or autonomous technology

Industry analysts claim that the robotic dental implant surgery will soon be the standard of care for implant procedures. Recently for instance, in 2017, Neocis a firm based in Miami, introduced the first robot-assisted dental surgical system called as Yomi. This new system uses software technology to plan an implant procedure based on the patient’s medical record and CT scan. Besides, the robot controls the direction of the drill and assists the clinics with accurate location, orientation, and depth of the implants.

On this note it is imperative to mention that a Chinese robot has performed the world’s first autonomous dental implant in 2017. According to reports, the robot assistant safely fixed two dental implants in a woman by following a pre-programmed set of commands. The implant surgery was successfully carried out by the robot dentist and was supervised by the dentists who did not play an active role in the procedure. Reports reveal that the dental robotic technology was designed to overcome China’s shortage of qualified dentists & rising rate of surgical errors.

Make Inquiry about this report @ https://www.gminsights.com/inquiry-before-buying/2684

The rapidly growing, well-established dental implants industry players across China and other such emerging nations has strongly impelled the growth statistics of the Asia Pacific dental implants market. Rapidly growing geriatric population along with rising awareness regarding oral health and dental tourism are further pushing the product demand in the region. Reports claim that the APAC implants market is predicted to register a y-o-y growth rate of 6.5% over 2018-2024.

3D printing technology

Another major technological impact in dentistry will be the use of additive manufacturing techniques. Several companies have been increasingly investing in 3D hyperelastic bone and other 3D printed techniques as they hold a lot of promise for patients that need bone grafting for customized implant placement.

One of the significant examples is that of Evo Dental, a London-based biotech company, that has secured £4 million from the British Growth Fund to advanced its 3D printing jaw correction clinic across the UK. Through its new clinic, the company aims to deliver its proprietary dental implant solution, featuring prosthesis additive manufacturing, digital scanning, and high-precision milling machines to the patients. 3D printing is particularly proving to be a growing technology in the regional dental implants industry, and companies such as Evo Dental are commendably leveraging this technological leap in the flourishing era of digital dentistry. According to a survey conducted by NHS’ Adult Dental Health, around 5 million people in UK could benefit from the deployment of such advanced technologies in dentistry.

Based on these trends, it wouldn’t be wrong to quote that the future of dental implants is paving the way for a much brighter scenario. The disruption of advanced technology and massive investment trends in this business sphere will provide a great opportunity to deliver dental implants of higher quality & at affordable costs. With innovative technologies, such as 3D printed prosthetics, robotic dentistry, and cloud-based dental practice management software promising better patient care, increased efficiency, and productive outcomes, dental implants market is expected to go a long way in the coming years. A report by Global Market Insights, Inc., states that the global dental implants market from its recent valuation of USD 3.7 billion in 2017 is estimated to surpass USD 5.2 billion by 2024.

Browse more reports :-

Tubeless Insulin Pump Market :- https://www.marketwatch.com/press-release/tubeless-insulin-pump-market-2019-detailed-analysis-of-current-industry-figures-with-forecasts-growth-by-2025-2019-09-20

Breast Implants Market :- https://www.marketwatch.com/press-release/breast-implants-market-global-industry-analysis-by-system-growth-potential-share-top-key-players-trends-forecast-to-2025-2019-09-20

Healthcare 3D Printing Market :- https://www.marketwatch.com/press-release/healthcare-3d-printing-market-2019-global-key-players-trends-share-industry-size-segmentation-opportunities-forecast-to-2025-2019-09-20

Over-the-Counter (OTC) Drugs Market :- https://www.marketwatch.com/press-release/over-the-counter-otc-drugs-market-industry-growth-analysis-forecast-by-2025-2019-09-20

News

NetApp to Participate in Upcoming Virtual Investor/Technology Conferences

gbafNews28

NetApp (NASDAQ: NTAP), a global cloud-led, data centric software company, today announced the Company will participate virtually in fireside chats at the following conferences:

Credit Suisse Technology Conference Mike Berry, executive vice president, finance and chief financial officer December 3, 2020 10:30 “ 11:00 a.m. Pacific Time

Barclays TMT Conference Mike Berry, executive vice president, finance and chief financial officer December 9, 2020 10:30 “ 10:55 a.m. Pacific Time

Live audio Webcasts of the presentations will be available at investors.netapp.com. An audio Webcast archive of each event will be available after the conferences.

About NetApp

NetApp is a global cloud-led, data-centric software company that empowers organizations to lead with data in the age of accelerated digital transformation. The company provides systems, software and cloud services that enable them to run their applications optimally from data center to cloud, whether they are developing in the cloud, moving to the cloud, or creating their own cloudlike experiences on premises. With solutions that perform across diverse environments, NetApp helps organizations build their own data fabric and securely deliver the right data, services and applications to the right peopleanytime, anywhere. Learn more at www.netapp.com or follow us on Twitter, LinkedIn, Facebook, and Instagram.

NETAPP, the NETAPP logo, and the marks listed at http://www.netapp.com/TM are trademarks of NetApp, Inc. Other company and product names may be trademarks of their respective owners.

Press Contact

Amelia Vierra

NetApp

1 408 822 6403

[email protected]

Investor Contact

Billie Fagenstrom

NetApp

1 408 822 6428

[email protected]

Continue Reading

News

Deciphera Pharmaceuticals, Inc. to Participate in the Piper Sandler 32nd Annual Virtual Healthcare Conference

gbafNews28

Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH), a commercial-stage biopharmaceutical company developing innovative medicines to improve the lives of people with cancer, today announced that Steve Hoerter, President and Chief Executive Officer, has participated in a fireside chat in advance of the Piper Sandler 32nd Annual Virtual Healthcare Conference, being held December 1-3, 2020.

A recording of the fireside chat is now available on the Events and Presentations page in the Investors section of the Companys website at https://investors.deciphera.com/news-events/events-presentations and will be available for 90 days.

About Deciphera Pharmaceuticals

Deciphera is a biopharmaceutical company focused on discovering, developing and commercializing important new medicines to improve the lives of people with cancer. We are leveraging our proprietary switch-control kinase inhibitor platform and deep expertise in kinase biology to develop a broad portfolio of innovative medicines. In addition to advancing multiple product candidates from our platform in clinical studies, QINLOCK is Decipheras FDA-approved switch-control kinase inhibitor for the treatment of fourth-line gastrointestinal stromal tumor (GIST). QINLOCK is also approved for fourth-line GIST in Canada and Australia. For more information, visit www.deciphera.com and follow us on LinkedIn and Twitter (@Deciphera).

Contacts:

Investor Relations:

Jen Robinson

Deciphera Pharmaceuticals, Inc.

[email protected]

781-906-1112

Media:

David Rosen

Argot Partners

[email protected]

212-600-1902

Continue Reading

News

Stoke Therapeutics Announces Closing of Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares

gbafNews28

Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company pioneering a new way to treat the underlying cause of genetic diseases by precisely upregulating protein expression, today announced the closing of its underwritten public offering of 2,875,000 shares of its common stock, including 375,000 shares sold upon full exercise of the underwriters option to purchase additional shares, at a price to the public of $39.00 per share. The net proceeds from the offering were approximately $105.1 million, after deducting underwriting discounts and commissions and estimated offering expenses.

J.P. Morgan Securities LLC, Cowen and Company, LLC, and Credit Suisse Securities (USA) LLC acted as joint book-running managers in the offering. Canaccord Genuity LLC and Cantor Fitzgerald & Co. acted as passive bookrunners in the offering.

Stoke intends to use the net proceeds from the proposed offering, together with its existing cash and cash equivalents, to fund research, clinical and process development and manufacturing of its product candidates, including late stage development of STK-001, clinical development of its next target for the treatment of Autosomal Dominant Optic Atrophy, developing additional product candidates, working capital, capital expenditures and other general corporate purposes.

The public offering was made pursuant to a registration statement on Form S-3 previously filed and declared effective by the Securities and Exchange Commission (the SEC). This offering was made solely by means of a prospectus supplement and accompanying prospectus relating to and describing the terms of the offering, copies of which may be obtained from: J.P. Morgan Securities LLC, c/o Broadridge Financial Services, Attention: Prospectus Department, 1155 Long Island Avenue, Edgewood, New York 11717, or by telephone: (866) 803-9204, or by emailing [email protected]; from Cowen and Company, LLC c/o Broadridge Financial Solutions, Attention: Prospectus Department, 1155 Long Island Avenue, Edgewood, New York 11717, or by telephone: (833) 297-2926, or by emailing [email protected]; or from Credit Suisse Securities (USA) LLC, Attention: Prospectus Department, 6933 Louis Stephens Drive, Morrisville, NC 27560, by telephone at (800) 221-1037, or by email at [email protected]. Electronic copies of the prospectus supplement and accompanying prospectus are available on the website of the SEC at http://www.sec.gov.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy any securities of Stoke, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

About Stoke Therapeutics

Stoke Therapeutics (Nasdaq: STOK) is a biotechnology company pioneering a new way to treat the underlying causes of severe genetic diseases by precisely upregulating protein expression to restore target proteins to near normal levels. Stoke aims to develop the first precision medicine platform to target the underlying cause of a broad spectrum of genetic diseases in which the patient has one healthy copy of a gene and one mutated copy that fails to produce a protein essential to health. These diseases, in which loss of approximately 50% of normal protein expression causes disease, are called autosomal dominant haploinsufficiencies. Stoke is headquartered in Bedford, Massachusetts with offices in Cambridge, Massachusetts.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by words such as: anticipate, intend, plan, goal, seek, believe, project, estimate, expect, strategy, future, likely, may, should, will and similar references to future periods. Examples of forward-looking statements include, among others, statements the Company makes regarding its expectation of market conditions, use of proceeds and Stokes plan to develop its precision medicine platform. All statements other than statements of historical fact are statements that could be deemed forward-looking statements. Although Stoke believes that the expectations reflected in such forward-looking statements are reasonable, Stoke cannot guarantee future events, results, actions, levels of activity, performance or achievements, and the timing and results of biotechnology development and potential regulatory approval is inherently uncertain. Forward-looking statements are subject to risks and uncertainties that may cause the Companys actual activities or results to differ significantly from those expressed in any forward-looking statement, including risks and uncertainties related to the impact of the COVID-19 pandemic on the Companys business, clinical trial sites, supply chain and manufacturing facilities, market conditions, the satisfaction of customary closing conditions related to the proposed offering, as well as other risks and uncertainties described under the heading Risk Factors in documents Stoke files from time to time with the SEC. These forward-looking statements speak only as of the date hereof and Stoke specifically disclaims any obligation to update these forward-looking statements or reasons why actual results might differ, whether as a result of new information, future events or otherwise, except as required by law.

Stoke Media & Investor Contact:

Dawn Kalmar

Vice President, Head of Corporate Affairs

[email protected]

781-303-8302

 

Continue Reading
Editorial & Advertiser disclosureOur website provides you with information, news, press releases, Opinion and advertorials on various financial products and services. This is not to be considered as financial advice and should be considered only for information purposes. We cannot guarantee the accuracy or applicability of any information provided with respect to your individual or personal circumstances. Please seek Professional advice from a qualified professional before making any financial decisions. We link to various third party websites, affiliate sales networks, and may link to our advertising partners websites. Though we are tied up with various advertising and affiliate networks, this does not affect our analysis or opinion. When you view or click on certain links available on our articles, our partners may compensate us for displaying the content to you, or make a purchase or fill a form. This will not incur any additional charges to you. To make things simpler for you to identity or distinguish sponsored articles or links, you may consider all articles or links hosted on our site as a partner endorsed link.
gbafNews28 gbafNews28
News24 mins ago

Raven Industries Reports Strong Third Quarter Fiscal 2021 Results

Raven Industries, Inc. (the Company; NASDAQ:RAVN) today reported financial results for the third quarter that ended October 31, 2020. Third...

gbafNews28 gbafNews28
News24 mins ago

Intuit CFO Michelle Clatterbuck to Present at Credit Suisse Technology Virtual Conference

Michelle Clatterbuck, chief financial officer of Intuit (Nasdaq: INTU) will present at the Credit Suisse Technology Virtual Conference on Dec....

gbafNews28 gbafNews28
News24 mins ago

Stoke Therapeutics Announces Closing of Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares

Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company pioneering a new way to treat the underlying cause of genetic diseases...

gbafNews28 gbafNews28
News24 mins ago

Deciphera Pharmaceuticals, Inc. to Participate in the Piper Sandler 32nd Annual Virtual Healthcare Conference

Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH), a commercial-stage biopharmaceutical company developing innovative medicines to improve the lives of people with cancer, today...

gbafNews28 gbafNews28
News24 mins ago

NetApp to Participate in Upcoming Virtual Investor/Technology Conferences

NetApp (NASDAQ: NTAP), a global cloud-led, data centric software company, today announced the Company will participate virtually in fireside chats...

gbafNews28 gbafNews28
News25 mins ago

Cottonseed Market Size, Industry Analysis Report, Regional Outlook, Application Development Potential, Price Trends, Competitive Market Share & Forecast, 2020 – 2024 | Technavio

The cottonseed market is poised to grow by USD 2.28 billion during 2020-2024, progressing at a CAGR of over 4%...

gbafNews28 gbafNews28
News25 mins ago

Intuit CEO Sasan Goodarzi to Present at Nasdaq Investor Conference

Sasan Goodarzi, chief executive officer of Intuit (Nasdaq: INTU) will present at the 43rd Nasdaq Investor Virtual Conference on Dec....

gbafNews28 gbafNews28
News30 mins ago

Strategy Analytics: Advancements in Wired and Wireless Connectivity Increase Power, Data for In-Car Infotainment Systems

Advancements in several key data and power delivery protocol standards bring a new level of convenience and capability to new...

gbafNews28 gbafNews28
News31 mins ago

Omnichannel Acquisition Corp. Announces Closing of $200 Million Initial Public Offering

Omnichannel Acquisition Corp. (the “Company”) today announced that it has closed its initial public offering of 20,000,000 units. The units...

gbafNews28 gbafNews28
News31 mins ago

The Concerned Shareholders of Rifco Inc. File and Mail Their Dissident Proxy Circular; All Shareholders Urged to Vote for a New Board Using the Blue Proxy

Tim Peterson, Ruth Peterson, 933672 Alberta Ltd. Sorbrick Capital Corp., 812787 Alberta Ltd., Big Country Holdings Ltd., Norman Storch and...